Abeona Therapeutics (ABEO) director Crombez granted 37,313 restricted shares

Rhea-AI Filing Summary

Abeona Therapeutics director Eric Crombez received a new equity grant. On January 26, 2026, he was awarded 37,313 shares of Abeona Therapeutics common stock as restricted stock at a price of $0.00 per share. After this grant, he directly owns 79,740 common shares.

The filing states that all of this restricted stock will vest on January 26, 2027, meaning the shares become fully earned on that date if vesting conditions are satisfied.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Crombez Eric

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	37,313	$0.00	--

Holdings After Transaction: Common Stock — 79,740 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Crombez Eric

(Last) (First) (Middle)

6555 CARNEGIE AVE., 4TH FLOOR

(Street)

CLEVELAND OH 44103

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ABEONA THERAPEUTICS INC. [ ABEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/26/2026		A		37,313(1)	A	$0.00	79,740	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. All of the restricted stock will vest on January 26, 2027.

	/s/ Eric Crombez	01/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Abeona Therapeutics (ABEO) disclose in this Form 4 filing?

Abeona Therapeutics reported that director Eric Crombez received 37,313 shares of restricted common stock. The award was granted at $0.00 per share and increased his direct holdings to 79,740 shares, with all granted shares scheduled to vest on January 26, 2027.

How many Abeona Therapeutics (ABEO) shares did Eric Crombez acquire?

Eric Crombez acquired 37,313 shares of Abeona Therapeutics common stock as a restricted stock award. These shares were recorded as an acquisition at no cash price per share and raised his directly held position to a total of 79,740 common shares following the transaction.

When do Eric Crombez’s Abeona Therapeutics (ABEO) restricted shares vest?

All 37,313 restricted shares awarded to Eric Crombez are scheduled to vest on January 26, 2027. Vesting means the restrictions on the stock lapse at that time, assuming any continued service or other conditions in the award agreement are satisfied by that date.

What type of transaction is reported for Abeona Therapeutics (ABEO) in this Form 4?

The Form 4 reports an “A” transaction code, indicating an acquisition of securities. In this case, it reflects a grant of 37,313 shares of restricted common stock to director Eric Crombez rather than an open-market purchase, with no cash price per share listed.

Does Eric Crombez hold Abeona Therapeutics (ABEO) shares directly or indirectly?

Eric Crombez’s holdings are reported as directly owned. After receiving the 37,313 restricted shares of Abeona Therapeutics common stock, his total directly held position is 79,740 shares, with no indirect ownership or related-entity holdings disclosed in this particular Form 4 filing.